[1]
|
徐近. 中国抗癌协会胰腺癌整合诊治指南(精简版) [J]. 中国肿瘤临床, 2023, 50(10): 487-496.
|
[2]
|
Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. https://doi.org/10.3322/caac.21763
|
[3]
|
孔冉. 胰腺导管腺癌的定量蛋白质组学研究[D]: [博士学位论文]. 北京: 军事科学院, 2023. https://doi.org/10.27193/d.cnki.gjsky.2022.000061
|
[4]
|
孙素芹, 叶婷, 樊蓉, 等. 《中国肿瘤整合诊治指南胰腺癌》出版: 山甲白花汤联合吉西他滨对胰腺癌小鼠肿瘤生长的抑制作用及其机制的研究[J]. 介入放射学杂志, 2023, 32(7): 727.
|
[5]
|
韩家伟. 胰腺癌新辅助/转化治疗后影响预后临床因素的筛选及预后模型的建立和验证[D]: [硕士学位论文]. 重庆: 中国人民解放军海军军医大学, 2023. https://doi.org/10.26998/d.cnki.gjuyu.2023.000192
|
[6]
|
Mostafa, M.E., Erbarut-Seven, I., Pehlivanoglu, B. and Adsay, V. (2017) Pathologic Classification of “Pancreatic Cancers”: Current Concepts and Challenges. Chinese Clinical Oncology, 6, 59-59. https://doi.org/10.21037/cco.2017.12.01
|
[7]
|
郝以杰, 高恒军, 牛哲禹, 等. 胰腺癌综合治疗的现状与进展[J]. 腹部外科, 2020, 33(6): 468-473.
|
[8]
|
Barros, A., Pulido, C., Machado, M., Brito, M., Couto, N., Sousa, O., et al. (2021) Treatment Optimization of Locally Advanced and Metastatic Pancreatic Cancer (Review). International Journal of Oncology, 59, 110. https://doi.org/10.3892/ijo.2021.5290
|
[9]
|
Burris, H.A., Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (2023) Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. Journal of Clinical Oncology, 41, 5482-5492. https://doi.org/10.1200/jco.22.02777
|
[10]
|
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., et al. (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine, 364, 1817-1825. https://doi.org/10.1056/nejmoa1011923
|
[11]
|
Von Hoff, D.D., Ervin, T., Arena, F.P., Chiorean, E.G., Infante, J., Moore, M., et al. (2013) Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine, 369, 1691-1703. https://doi.org/10.1056/nejmoa1304369
|
[12]
|
Raphael, M.J., Raskin, W., Habbous, S., Tai, X., Beca, J., Dai, W.F., et al. (2021) The Association of Drug-Funding Reimbursement with Survival Outcomes and Use of New Systemic Therapies among Patients with Advanced Pancreatic Cancer. JAMA Network Open, 4, e2133388. https://doi.org/10.1001/jamanetworkopen.2021.33388
|
[13]
|
Wang-Gillam, A., Li, C., Bodoky, G., Dean, A., Shan, Y., Jameson, G., et al. (2016) Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer after Previous Gemcitabine-Based Therapy (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial. The Lancet, 387, 545-557. https://doi.org/10.1016/s0140-6736(15)00986-1
|
[14]
|
陈哲然, 辛磊, 王洛伟. 《2023年欧洲肿瘤内科学会临床实践指南: 胰腺癌的诊断、治疗和随访》意见要点[J]. 临床肝胆病杂志, 2023, 39(12): 2804-2808.
|
[15]
|
Hosein, A.N., Brekken, R.A. and Maitra, A. (2020) Pancreatic Cancer Stroma: An Update on Therapeutic Targeting Strategies. Nature Reviews Gastroenterology & Hepatology, 17, 487-505. https://doi.org/10.1038/s41575-020-0300-1
|
[16]
|
Moradi Kashkooli, F., Soltani, M. and Souri, M. (2020) Controlled Anti-Cancer Drug Release through Advanced Nano-Drug Delivery Systems: Static and Dynamic Targeting Strategies. Journal of Controlled Release, 327, 316-349. https://doi.org/10.1016/j.jconrel.2020.08.012
|
[17]
|
戴亮亮. 纳米介孔硅及聚合物胶束智能药物递送系统制备与抗肿瘤效应研究[D]: [博士学位论文]. 重庆: 重庆大学, 2019. https://kns.cnki.net/KCMS/detail/detail.aspx?dbcode=CDFD&dbname=CDFDLAST2019&filename=1018852833.nh, 2024-04-30.
|
[18]
|
Liu, L., Kshirsagar, P.G., Gautam, S.K., Gulati, M., Wafa, E.I., Christiansen, J.C., et al. (2022) Nanocarriers for Pancreatic Cancer Imaging, Treatments, and Immunotherapies. Theranostics, 12, 1030-1060. https://doi.org/10.7150/thno.64805
|
[19]
|
Raza, F., Evans, L., Motallebi, M., Zafar, H., Pereira-Silva, M., Saleem, K., et al. (2023) Liposome-Based Diagnostic and Therapeutic Applications for Pancreatic Cancer. Acta Biomaterialia, 157, 1-23. https://doi.org/10.1016/j.actbio.2022.12.013
|
[20]
|
Su, J., Sun, H., Meng, Q., Zhang, P., Yin, Q. and Li, Y. (2017) Enhanced Blood Suspensibility and Laser-Activated Tumor-Specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Theranostics, 7, 523-537. https://doi.org/10.7150/thno.17259
|
[21]
|
Hoang Thi, T.T., Cao, V.D., Nguyen, T.N.Q., Hoang, D.T., Ngo, V.C. and Nguyen, D.H. (2019) Functionalized Mesoporous Silica Nanoparticles and Biomedical Applications. Materials Science and Engineering: C, 99, 631-656. https://doi.org/10.1016/j.msec.2019.01.129
|
[22]
|
Kankala, R.K., Han, Y., Na, J., Lee, C., Sun, Z., Wang, S., et al. (2020) Nanoarchitectured Structure and Surface Biofunctionality of Mesoporous Silica Nanoparticles. Advanced Materials, 32, Article ID: 1907035. https://doi.org/10.1002/adma.201907035
|
[23]
|
Yin, F., Zhang, B., Zeng, S., Lin, G., Tian, J., Yang, C., et al. (2015) Folic Acid-Conjugated Organically Modified Silica Nanoparticles for Enhanced Targeted Delivery in Cancer Cells and Tumor in Vivo. Journal of Materials Chemistry B, 3, 6081-6093. https://doi.org/10.1039/c5tb00587f
|
[24]
|
Wang, C.E., Stayton, P.S., Pun, S.H. and Convertine, A.J. (2015) Polymer Nanostructures Synthesized by Controlled Living Polymerization for Tumor-Targeted Drug Delivery. Journal of Controlled Release, 219, 345-354. https://doi.org/10.1016/j.jconrel.2015.08.054
|
[25]
|
Tarannum, M., Holtzman, K., Dréau, D., Mukherjee, P. and Vivero-Escoto, J.L. (2022) Nanoparticle Combination for Precise Stroma Modulation and Improved Delivery for Pancreatic Cancer. Journal of Controlled Release, 347, 425-434. https://doi.org/10.1016/j.jconrel.2022.05.019
|
[26]
|
Asefa, T. and Tao, Z. (2012) Biocompatibility of Mesoporous Silica Nanoparticles. Chemical Research in Toxicology, 25, 2265-2284. https://doi.org/10.1021/tx300166u
|
[27]
|
Patra, A., Satpathy, S. and Hussain, M.D. (2019) Nanodelivery and Anticancer Effect of a Limonoid, Nimbolide, in Breast and Pancreatic Cancer Cells. International Journal of Nanomedicine, 14, 8095-8104. https://doi.org/10.2147/ijn.s208540
|
[28]
|
Feltrin, F.d.S., Agner, T., Sayer, C. and Lona, L.M.F. (2022) Curcumin Encapsulation in Functional PLGA Nanoparticles: A Promising Strategy for Cancer Therapies. Advances in Colloid and Interface Science, 300, Article ID: 102582. https://doi.org/10.1016/j.cis.2021.102582
|
[29]
|
Mir, M., Ahmed, N. and Rehman, A.U. (2017) Recent Applications of PLGA Based Nanostructures in Drug Delivery. Colloids and Surfaces B: Biointerfaces, 159, 217-231. https://doi.org/10.1016/j.colsurfb.2017.07.038
|
[30]
|
Hu, Y., Chen, X., Xu, Y., Han, X., Wang, M., Gong, T., et al. (2019) Hierarchical Assembly of Hyaluronan Coated Albumin Nanoparticles for Pancreatic Cancer Chemoimmunotherapy. Nanoscale, 11, 16476-16487. https://doi.org/10.1039/c9nr03684a
|
[31]
|
Yu, Q., Tang, X., Zhao, W., Qiu, Y., He, J., Wan, D., et al. (2021) Mild Hyperthermia Promotes Immune Checkpoint Blockade-Based Immunotherapy against Metastatic Pancreatic Cancer Using Size-Adjustable Nanoparticles. Acta Biomaterialia, 133, 244-256. https://doi.org/10.1016/j.actbio.2021.05.002
|
[32]
|
Bhushan, B., Khanadeev, V., Khlebtsov, B., Khlebtsov, N. and Gopinath, P. (2017) Impact of Albumin Based Approaches in Nanomedicine: Imaging, Targeting and Drug Delivery. Advances in Colloid and Interface Science, 246, 13-39. https://doi.org/10.1016/j.cis.2017.06.012
|
[33]
|
张俊. 褐藻多糖硫酸酯对人黑色素瘤A375系细胞活性的影响及其机制探讨[D]: [硕士学位论文]. 泸州: 西南医科大学, 2021. https://doi.org/10.27215/d.cnki.glzyu.2017.000059
|
[34]
|
Barbosa, A.I., Costa Lima, S.A. and Reis, S. (2019) Application of Ph-Responsive Fucoidan/Chitosan Nanoparticles to Improve Oral Quercetin Delivery. Molecules, 24, Article No. 346. https://doi.org/10.3390/molecules24020346
|
[35]
|
Wang, Y., Xing, M., Cao, Q., Ji, A., Liang, H. and Song, S. (2019) Biological Activities of Fucoidan and the Factors Mediating Its Therapeutic Effects: A Review of Recent Studies. Marine Drugs, 17, Article No. 183. https://doi.org/10.3390/md17030183
|
[36]
|
Etman, S.M., Abdallah, O.Y. and Elnaggar, Y.S.R. (2020) Novel Fucoidan Based Bioactive Targeted Nanoparticles from Undaria Pinnatifida for Treatment of Pancreatic Cancer. International Journal of Biological Macromolecules, 145, 390-401. https://doi.org/10.1016/j.ijbiomac.2019.12.177
|
[37]
|
Channon, L.M., Tyma, V.M., Xu, Z., Greening, D.W., Wilson, J.S., Perera, C.J., et al. (2022) Small Extracellular Vesicles (Exosomes) and Their Cargo in Pancreatic Cancer: Key Roles in the Hallmarks of Cancer. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1877, Article ID: 188728. https://doi.org/10.1016/j.bbcan.2022.188728
|
[38]
|
Ensminger, W.D. (2002) Intrahepatic Arterial Infusion of Chemotherapy: Pharmacologic Principles. Seminars in Oncology, 29, 119-125. https://doi.org/10.1053/sonc.2002.31679
|
[39]
|
Groot Koerkamp, B., Sadot, E., Kemeny, N.E., Gönen, M., Leal, J.N., Allen, P.J., et al. (2017) Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated with Longer Survival after Resection of Colorectal Liver Metastases: A Propensity Score Analysis. Journal of Clinical Oncology, 35, 1938-1944. https://doi.org/10.1200/jco.2016.71.8346
|
[40]
|
Ohigashi, H., Ishikawa, O., Eguchi, H., Sasaki, Y., Yamada, T., Noura, S., et al. (2005) Feasibility and Efficacy of Combination Therapy with Preoperative and Postoperative Chemoradiation, Extended Pancreatectomy, and Postoperative Liver Perfusion Chemotherapy for Locally Advanced Cancers of the Pancreatic Head. Annals of Surgical Oncology, 12, 629-636. https://doi.org/10.1245/aso.2005.05.028
|
[41]
|
Schizas, D., Charalampakis, N., Kole, C., Economopoulou, P., Koustas, E., Gkotsis, E., et al. (2020) Immunotherapy for Pancreatic Cancer: A 2020 Update. Cancer Treatment Reviews, 86, Article ID: 102016. https://doi.org/10.1016/j.ctrv.2020.102016
|
[42]
|
Bayne, L.J., Beatty, G.L., Jhala, N., Clark, C.E., Rhim, A.D., Stanger, B.Z., et al. (2012) Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer. Cancer Cell, 21, 822-835. https://doi.org/10.1016/j.ccr.2012.04.025
|
[43]
|
Michelakos, T., Cai, L., Villani, V., Sabbatino, F., Kontos, F., Fernández-del Castillo, C., et al. (2020) Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. JNCI: Journal of the National Cancer Institute, 113, 182-191. https://doi.org/10.1093/jnci/djaa073
|
[44]
|
Li, K., Tandurella, J.A., Gai, J., Zhu, Q., Lim, S.J., Thomas, D.L., et al. (2022) Multi-Omic Analyses of Changes in the Tumor Microenvironment of Pancreatic Adenocarcinoma Following Neoadjuvant Treatment with Anti-PD-1 Therapy. Cancer Cell, 40, 1374-1391.e7. https://doi.org/10.1016/j.ccell.2022.10.001
|
[45]
|
Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., et al. (2017) An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma. Nature, 547, 217-221. https://doi.org/10.1038/nature22991
|
[46]
|
Beatty, G.L., Haas, A.R., Maus, M.V., Torigian, D.A., Soulen, M.C., Plesa, G., et al. (2014) Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies. Cancer Immunology Research, 2, 112-120. https://doi.org/10.1158/2326-6066.cir-13-0170
|
[47]
|
O'Neil, N.J., Bailey, M.L. and Hieter, P. (2017) Synthetic Lethality and Cancer. Nature Reviews Genetics, 18, 613-623. https://doi.org/10.1038/nrg.2017.47
|
[48]
|
Jones, S., Zhang, X., Parsons, D.W., et al. (2008) Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science (New York, N.Y.), 321, 1801-1806.
|
[49]
|
Qian, Z.R., Rubinson, D.A., Nowak, J.A., Morales-Oyarvide, V., Dunne, R.F., Kozak, M.M., et al. (2018) Association of Alterations in Main Driver Genes with Outcomes of Patients with Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 4, e173420. https://doi.org/10.1001/jamaoncol.2017.3420
|
[50]
|
Corcoran, R.B., Cheng, K.A., Hata, A.N., Faber, A.C., Ebi, H., Coffee, E.M., et al. (2013) Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 23, 121-128. https://doi.org/10.1016/j.ccr.2012.11.007
|
[51]
|
Cocco, E., Scaltriti, M. and Drilon, A. (2018) NTRK Fusion-Positive Cancers and TRK Inhibitor Therapy. Nature Reviews Clinical Oncology, 15, 731-747. https://doi.org/10.1038/s41571-018-0113-0
|
[52]
|
Bykov, V.J.N., Eriksson, S.E., Bianchi, J. and Wiman, K.G. (2017) Targeting Mutant P53 for Efficient Cancer Therapy. Nature Reviews Cancer, 18, 89-102. https://doi.org/10.1038/nrc.2017.109
|
[53]
|
Shi, Y., Hata, A., Lo, R.S., Massagué, J. and Pavletich, N.P. (1997) A Structural Basis for Mutational Inactivation of the Tumour Suppressor Smad4. Nature, 388, 87-93. https://doi.org/10.1038/40431
|
[54]
|
Sanjabi, S., Oh, S.A. and Li, M.O. (2017) Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. Cold Spring Harbor Perspectives in Biology, 9, a022236. https://doi.org/10.1101/cshperspect.a022236
|
[55]
|
Shi, L., Sheng, J., Wang, M., Luo, H., Zhu, J., Zhang, B., et al. (2019) Combination Therapy of TGF-β Blockade and Commensal-Derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression. Theranostics, 9, 4115-4129. https://doi.org/10.7150/thno.35131
|
[56]
|
Heger, U. and Hackert, T. (2021) Can Local Ablative Techniques Replace Surgery for Locally Advanced Pancreatic Cancer? Journal of Gastrointestinal Oncology, 12, 2536-2546. https://doi.org/10.21037/jgo-20-379
|
[57]
|
李茂全. 晚期胰腺癌介入治疗临床操作指南(试行) (第六版) [J]. 临床肝胆病杂志, 2022, 38(6): 1242-1251.
|
[58]
|
Ruarus, A., Vroomen, L., Puijk, R., Scheffer, H. and Meijerink, M. (2018) Locally Advanced Pancreatic Cancer: A Review of Local Ablative Therapies. Cancers, 10, Article No. 16. https://doi.org/10.3390/cancers10010016
|
[59]
|
He, L., Niu, L., Korpan, N.N., Sumida, S., Xiao, Y., Li, J., et al. (2017) Clinical Practice Guidelines for Cryosurgery of Pancreatic Cancer. Pancreas, 46, 967-972. https://doi.org/10.1097/mpa.0000000000000878
|
[60]
|
李竞, 张肖, 张啸波, 等. 纳米刀消融联合程序性死亡蛋白-1/程序性死亡蛋白配体-1治疗胰腺癌及其免疫学机制研究进展[J/OL]. 中国介入影像与治疗学, 2020, 17(10): 628-631. https://doi.org/10.13929/j.issn.1672-8475.2020.10.012
|
[61]
|
Wang, J., Wang, Y., Zhao, Y., Wu, X., Zhang, M., Hou, W., et al. (2021) Endoscopic Ultrasound-Guided Radiofrequency Ablation of Unresectable Pancreatic Cancer with Low Ablation Power and Multiple Applications: A Preliminary Study of 11 Patients. Annals of Palliative Medicine, 10, 1842-1850. https://doi.org/10.21037/apm-20-1468
|
[62]
|
Yang, J., Zhang, X., Jiang, J. and Lou, Q. (2021) Feasibility and Safety of EUS-Guided Radiofrequency Ablation in Treatment of Locally Advanced, Unresectable Pancreatic Cancer. Endoscopic Ultrasound, 10, 398-399. https://doi.org/10.4103/eus-d-21-00013
|
[63]
|
Pai, M. (2015) Endoscopic Ultrasound Guided Radiofrequency Ablation, for Pancreatic Cystic Neoplasms and Neuroendocrine Tumors. World Journal of Gastrointestinal Surgery, 7, 52-59. https://doi.org/10.4240/wjgs.v7.i4.52
|
[64]
|
Poulou, L.S. (2015) Percutaneous Microwave Ablation vs Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma. World Journal of Hepatology, 7, 1054-1063. https://doi.org/10.4254/wjh.v7.i8.1054
|
[65]
|
Glassberg, M.B., Ghosh, S., Clymer, J.W., Qadeer, R.A., Ferko, N.C., Sadeghirad, B., et al. (2019) Microwave Ablation Compared with Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma and Liver Metastases: A Systematic Review and Meta-Analysis. OncoTargets and Therapy, 12, 6407-6438. https://doi.org/10.2147/ott.s204340
|
[66]
|
Di Matteo, F.M., Saccomandi, P., Martino, M., Pandolfi, M., Pizzicannella, M., Balassone, V., et al. (2018) Feasibility of EUS-Guided ND:YAG Laser Ablation of Unresectable Pancreatic Adenocarcinoma. Gastrointestinal Endoscopy, 88, 168-174.e1. https://doi.org/10.1016/j.gie.2018.02.007
|
[67]
|
Wang, Y., Wang, H., Zhou, L., Lu, J., Jiang, B., Liu, C., et al. (2020) Photodynamic Therapy of Pancreatic Cancer: Where Have We Come from and Where Are We Going? Photodiagnosis and Photodynamic Therapy, 31, Article ID: 101876. https://doi.org/10.1016/j.pdpdt.2020.101876
|
[68]
|
DeWitt, J.M., Sandrasegaran, K., O’Neil, B., House, M.G., Zyromski, N.J., Sehdev, A., et al. (2019) Phase 1 Study of EUS-Guided Photodynamic Therapy for Locally Advanced Pancreatic Cancer. Gastrointestinal Endoscopy, 89, 390-398. https://doi.org/10.1016/j.gie.2018.09.007
|
[69]
|
Iwasaki, E., Fukuhara, S., Horibe, M., Kawasaki, S., Seino, T., Takimoto, Y., et al. (2021) Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Diagnostics, 11, Article No. 469. https://doi.org/10.3390/diagnostics11030469
|
[70]
|
Tempero, M.A., Malafa, M.P., Al-Hawary, M., Behrman, S.W., Benson, A.B., Cardin, D.B., et al. (2021) Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 439-457. https://doi.org/10.6004/jnccn.2021.0017
|
[71]
|
Spiliopoulos, S., Reppas, L., Filippiadis, D., Delvecchio, A., Conticchio, M., Memeo, R., et al. (2023) Irreversible Electroporation for the Management of Pancreatic Cancer: Current Data and Future Directions. World Journal of Gastroenterology, 29, 223-231. https://doi.org/10.3748/wjg.v29.i2.223
|
[72]
|
Xiao, Y., Wang, Z., Hu, X., Wei, Y., Chen, G., Ding, X., et al. (2021) Chinese Expert Consensus of Image-Guided Irreversible Electroporation for Pancreatic Cancer. Journal of Cancer Research and Therapeutics, 17, 613-618. https://doi.org/10.4103/jcrt.jcrt_1663_20
|